Improving the therapeutic efficacy of T cells expressing a chimeric antigen receptor (CAR) represents an important goal in efforts to control B-cell malignancies. Recently an intrinsic strategy has been developed to modify the CAR itself to improve T-cell signaling. Here we report a second extrinsic approach based on altering the culture milieu to numerically expand CAR þ
Introduction
Adoptive transfer of antigen-specific T cells has been used to treat and prevent malignancies and opportunistic infections. To overcome immune tolerance to human tumor-associated antigens (TAA), investigators have redirected specificity through the introduction of immunoreceptors. An initial clinical trial showed the safety and feasibility of redirecting T cell specificity to CD19, a TAA expressed on B-cell malignancies (1) (2) (3) . These clinical data demonstrated that infused T cells were short lived due, in part, to the use of a firstgeneration chimeric antigen receptor (CAR) that recognized CD19 independent of MHC via chimeric CD3-z (signal 1). In response, we developed a second-generation CD19-specific CAR to activate T cells through both CD3-z and CD28 endodomains (signals 1 and 2, respectively) to improve T-cell activation (4) . To translate this CAR to clinical trials, we established a platform for nonviral gene transfer using the Sleeping Beauty (SB) system and subsequent selective expansion of CAR þ T cells recursively cocultured upon CD19 þ artificial antigenpresenting cells (aAPC) modified from K562 to express CD19 and desired costimulatory molecules (5) (6) (7) . In addition to modifying the CAR itself to augment therapeutic potential, we have now manipulated the tissue culture environment to alter the types of CAR þ T cells that can be generated. We investigated whether cytokines could be added to cultures to provide a "signal 3" to improve the CAR þ T cells response to B-cell malignancies.
One attractive cytokine to use in the culturing of T cells is interleukin (IL)-21, which like IL-2, signals through the cytokine receptor common g chain (IL-2Rg). This was selected to be tested on the basis of the published work showing that this cytokine increases tumor-specific T cells (8) and/or natural killer (NK) cells (9, 10) leading to antitumor immunity in animal models. Further, IL-21 provides a T-cell survival signal and can act in conjunction with CD28 to support proliferation and acquisition of effector functions (11) . T cells genetically modified to have enforced secretion of IL-21 exhibited improved antitumor effect compared to T cells not modified to secrete cytokines (12) . Recombinant soluble IL-21 has been intravenously administered in patients with metastatic renal cell carcinoma, melanoma, and lymphoma, and antitumor activity has been observed (13) . In contrast to IL-2, IL-21 also inhibits generation of human regulatory T cells in vitro (14) .
We hypothesized that altering the culture environment by the addition of IL-21 will lead to improved numeric expansion and functionality of CD19-specific CAR þ T cells. When IL-21
was present with or on aAPC, we found there was a preferential numeric expansion of CAR þ T cells with a preference to propagate subpopulations of (i) CD8 þ T cells, (ii) memory T cells, and (iii) naïve T cells, which lysed and produced IFN-g in response to CD19. This resulted in improved control of CD19 þ tumor in a mouse model of human T-cell immunotherapy.
Materials and Methods

Plasmids
The SB transposon CoOp CD19RCD28/pSBSO expresses the human codon optimized (CoOp) second generation CoOp CD19RCD28 CAR under human elongation factor 1-a (hEF-1a) promoter, flanked by the SB inverted repeats (6) . To generate membrane-bound IL-21 (mIL-21), the GM-CSF (granulocyte macrophage-colony-stimulating factor) signal peptide sequence was directly fused to the coding sequence of mature human IL-21 which was attached via a modified [amino acid (aa) 108, Ser ! Pro] 12 aa IgG4 hinge region (aa 99-110), to the 5 0 end of a human immunoglobulin g-4 chain C H 2 and C H 3 regions (aa 111-327, UniProtKB P01861), that was fused in frame to human CD4 transmembrane domain (aa 397-418, UniProtKB P01730). After validating the sequence, the human codon optimized cDNA (GENEART) was cloned as a transposon into a SB expression plasmid, pT-MNDU3-eGFP (5) replacing the eGFP sequence to obtain CoOp IL-21-Fc/pT-MNDU3 (Fig. 6A) . The SB transposase, SB11 is expressed in cis from the plasmid pCMV-SB11 (6). (5, 6) . NALM-6 cells were transduced using a murine stem cell virus-based retroviral vector encoding enhanced firefly luciferase (effLuc; ref. 17) fused with enhanced green fluorescent protein (EGFP; a kind gift from Dr Brian Rabinovich, MDACC). Retrovirus was packaged as previously described (17) , concentrated 50Â using Amicon Ultra-15 100,000 NMWL centrifugal concentration units (Millipore), mixed with NALM-6 cells in the presence of 8 mg/mL polybrene (Sigma) and spinfected for 90 minutes at 2200 RPM/30 C. One week later, EGFP þ NALM-6 cells were sorted on a FACSAria (BD Biosciences). Selective in vitro expansion of genetically modified T cells was carried out using K562-derived aAPC (clone no. 4) coexpressing CD19, CD64, CD86, CD137L, and a membranebound IL-15 (mIL-15; coexpressed with EGFP; ref. 15) . Clone no. 4 was further modified to express mIL-21 using the construct CoOp IL-21-Fc/pT-MNDU3. Briefly, 10 6 aAPC were resuspended in 100 mL Amaxa Cell Line Nucleofector Solution V (catalogue no. VPA-1003) along with transposon ( CoOp IL-21-Fc/pT-MNDU3, 2 mg) and SB transposase (pCMV-SB11, 2 mg) DNA supercoiled plasmids, transferred to a cuvette and electroporated (Program T-16) using Nucleofector II (Lonza). The transfectants were cultured for a week in complete media and a clone (D2) was obtained by plating at limited dilution after FACS (fluorescence-activated cell sorter) sorting. All cell lines were verified by morphology and/or flow cytometry, tested for Mycoplasma, and conserved in research cell bank on reception.
Cell lines and their propagation
Generation of CAR
þ T cells CD19-specific CAR þ T cells were generated from peripheral blood mononuclear cells (PBMC) using SB transposition as previously described and depicted in Figure 1 (5). Briefly, 10 7 to 2 Â 10 7 mononuclear cells, isolated from blood by FicollPaque density gradient centrifugation (GE Healthcare BioSciences AB), were resuspended in 100 mL of Amaxa Nucleofector solution (Human T cell Kit, catalogue no. VPA-1002), along with CAR transposon (CD19RCD28/pSBSO, 15 mg) and SB transposase (pCMV-SB11, 5 mg) DNA plasmids, transferred to a single cuvette and electroporated (Program U-14) on day 0 using Nucleofector II. The cells were rested for 2 to 3 hours at 37 C in incomplete phenol-free RPMI (HyClone) and subsequently cultured overnight in phenol-free RPMI containing 10% FBS and stimulated the next day (day 1) with g-irradiated (100 Gy) K562-aAPC at a 1:2 T cell/aAPC ratio. Additional g-irradiated aAPC clone no. 4 were added every 7 days at the same ratio. When used, soluble recombinant human IL-21 (catalogue no. 34-8219-85, eBioscience) was added at a concentration of 30 ng/mL beginning the day after electroporation, and soluble recombinant human IL-2 (IL-2; Chiron) was added to the cultures at 50 U/mL beginning 7 days after electroporation. For experiments where CAR þ T cells were cocultured on mIL-21 þ K562-aAPC (T cell/aAPC clone D2 ratio 1:2), IL-2 (50 U/mL) was added to the cultures on day 7 after electroporation. All exogenous cytokines continued to be supplemented on a Monday-Wednesday-Friday schedule for 7-day stimulation cycles marked by the addition of aAPC. 
Flow cytometry
Up to 10 6 cells in 100 mL volume were stained with fluorochrome-conjugated [fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein conjugated to cyanine dye (PerCPCy5.5), allophycocyanin (APC)] reagents which unless otherwise stated, were obtained from BD Biosciences: anti-CD3 FITC (catalogue no. 349201, 5 mL), anti-CD3 PerCPCy5.5 (catalogue no. 340949, 4 mL), anti-CD4 APC (catalogue no. 555349, 2.5 mL), anti-CD8 PerCPCy5.5 (catalogue no. 341051, 4 mL), anti-CD19 PE (catalogue no. 555413, 10 mL), anti-CD28 PerCPCy5.5 (catalogue no. 337181, 4 mL), anti-CD62L APC (catalogue no. 559772, 2.5 mL), anti-CD45RA FITC (catalogue no. 555488, 5 mL), anti-CD45RO APC (catalogue no. 559865, 2.5 mL), anti-IL7Ra Alexa Fluor 647 (catalog no. 558598, 10 mL), anti-PD1 APC (catalogue no. 558694, 2.5 mL), anti-PDL1 PE (catalogue no. 557924, 2.5 mL), anti-NKG2D PE (catalogue no. 557940, 2.5 mL), anti-Granzyme B Alexa Fluor 647 (catalogue no. 560212, 3 mL), anti-Perforin PE (Reagent Set no. 556437, 3 mL), anti-HLA (human leukocyte antigen)-ABC APC (catalogue no. 555555, 2.5 mL), anti-CD86 PE (catalogue no. 555658, 2.5 mL), anti-CD64 PE (catalogue no. 558592, 2.5 mL), anti-CD137L PE (catalogue no. 559446, 2.5 mL), anti-IFN-g APC (catalogue no. 554702, 2 mL), anti-pSTAT3 (pY705) PE (catalogue no. 612569, 20 mL), anti-IL-21 PE (catalogue no. 12 7219-73, 2.5 mL, eBiosciences), anti-CCR7 PE (catalogue no. FAB197P, 10 mL, R&D Systems) and anti-CXCR4 PE (catalogue no. FAB173P, 10mL, R&D Systems). FITC-conjugated (catalogue no. H10101C, 3 mL, Invitrogen) and PE-conjugated (catalogue no. H10104, 2.5 mL, Invitrogen) F(ab 0 ) 2 fragment of goat anti-human Fcg was used to detect cell surface expression of the CD19-specific CAR. Blocking of nonspecific antibody binding was achieved using FACS wash buffer (2% FBS and 0.1% Sodium azide in PBS). Data acquisition was on a FACSCalibur (BD Biosciences) using CellQuest version 3.3 (BD Biosciences). Analyses and calculation of median fluorescence intensity (MFI) was undertaken using FCS Express version 3.00.007 (Thornhill).
Chromium release assay
The cytolytic activity of T cells was determined in a standard 4-hour chromium release assay (CRA) as described previously (5, 18) . Biosciences) diluted in water at 37 C for 10 minutes to prevent dephosphorylation. Thereafter, pelleted cells were permeabilized by adding BD PhosFlow Perm Buffer III (catalogue no. 55850, BD Biosciences) for 20 minutes on ice, followed by washing with BD Pharmingen Staining Buffer (catalogue no. 554656). Resuspended cells were then stained with antibodies for pSTAT3, CD3, and CAR for 20 minutes in the dark, washed once with BD Pharmingen Staining Buffer, and resuspended in the same buffer for flow cytometry analysis.
nCounter analysis digital gene expression system
Genetically modified T cells (10,000) were lysed in RNeasy lysis buffer (RLT; 5 mL, Qiagen) and frozen for single-use aliquots at À80 C. Lysates were thawed and the selected mRNA content analyzed using the nCounter Analysis System (model no. NCT-SYST-120, NanoString Technologies; ref. 19) after hybridization with a designer reporter code set and capture probe set for 12 hours at 65 C. The probes were designed, synthesized, and hybridized using the nCounter Gene Expression Assay Kit. The posthybridization processing was undertaken using the nCounter Prep Station. Nanominer software was used to carry out normalization compared to internal control and basic statistical analysis on the data. The normalized results are expressed as the relative mRNA level.
In vivo efficacy of CAR þ T cells
On day 0, 7-week-old NOD.Cg-Prkdc (20). Photons emitted from NALM-6 xenografts were serially quantified using the Living Image 2.50.1 (Caliper Life Sciences) program. At the end of the experiment, mice were euthanized and tissues harvested. Bone marrow was flushed from the femurs using 30Gx 1 / 2 inch needles (BD, catalogue no. 305106) with 2% FBS in PBS. Spleens were disrupted using a syringe in 2% FBS/PBS and passed through a 40 mm nylon cell strainer (BD, catalogue no. 352340) to obtain single cell suspension. Red blood cells from bone marrow, spleen, and peripheral blood were lysed using ACK lysing buffer (Gibco-Invitrogen, A10492) and remaining cells stained for presence of tumor (CD19 and EGFP) by flow cytometry. Statistical analysis of photon flux and tumor burden was accomplished using Student's t test.
Results
Propagation of CAR þ T cells with IL-21
A master cell-bank of clinical-grade K562-derived aAPC, designated clone no. 4, has been generated through the Production Assistance for Cellular Therapies (PACT) to propagate CD19-specific CAR þ T cells to clinically sufficient numbers.
These g-irradiated aAPC selectively propagate CAR þ T cells after the electrotransfer of SB plasmids coding for CD19RCD28 CAR (5). To investigate extrinsic factors that might improve the therapeutic potential of CAR þ T cells, a role for IL-21 was examined in the culturing process on aAPC. We added this soluble cytokine, in addition to soluble IL-2 and mIL-15 on aAPC, and showed selective expansion of CAR þ T cells ( Fig. 2A) . This resulted in a greater number of CD3 þ and CAR þ T cells at 28 days of coculture on clone no. 4
(P < 0.05) compared with T cells receiving IL-2 alone, with differences between the 2 groups already apparent within 2 weeks after electroporation ( Fig. 2B and C) (Fig. 2) . The T cells receiving IL-21 had 1.8-fold higher number of average CD8 þ T cells (24.2 AE 25.
3) compared to the T cells receiving just IL-2 (13.4 AE 0.9) at day 28 of coculture ( Fig. 3D) . At the time of analysis, there was increased CAR expression on the T cells exposed to IL-21 compared to T cells cultured with only IL-2 (mean 90% AE 7.5 vs. 66% AE 7; P < 0.01) which indicates that manipulating the cytokine milieu can improve the outgrowth of T cells with increased expression of CAR (Fig. 3C) . In aggregate, the addition of IL-21 compared to culturing only with IL-2, results in T cells containing subpopulations that have improved effector function, a trend toward CD8 þ phenotype, and augmented CAR expression.
IL-21 results in propagation of subpopulations of CAR
þ T cells with memory and naïve phenotypes T cells propagated over a prolonged time in tissue culture tend to mature to a differentiated phenotype which may compromise their therapeutic potential. To determine if IL-21 can curtail this differentiation of genetically modified T cells, we examined the expression of (i) eomesodermin (EOMES) which controls cytolytic development and function of T cells, and has recently been shown to be reduced in naïve-derived effector cells (22) (23) (24) and (ii) killer cell lectin-like receptor subfamily G, member 1 (KLRG1), an inhibitory receptor that is expressed by senescent T cells (25, 26) . At day 28, the T cells cultured only with IL-2 had increased levels of mRNA species coding for EOMES and KLRG1 showing that this cytokine promoted differentiation of CAR þ T cells on aAPC. However, when IL-21 was added there was a 7-fold and 54-fold reduction in EOMES and KLRG1, respectively (Fig. 3A) . To expand on the mRNA data, we examined the cell surface expression for flow cytometry markers of naïve, memory, and differentiated T cells. A naïve phenotype was defined by the presence of CD62L and CD45RA, whereas a central memory (T CM ) phenotype can be defined by the expression of CD28, CD62L, CCR7, and CD45RO on T cells (27) (28) (29) . Differentiated effector cells typically lose expression of these markers upon prolonged culturing, and exhausted cells upregulate expression of PD-1 and PDL-1 (30) . CAR þ T cells grown in the presence of IL-2 and IL-21 exhibited markers consistent with both naïve and memory cells and lacked expression of PD-1/PDL-1 (Fig. 4A ). In addition, the lack of (2%) CD57 expression supports absence of exhaustion among the CAR þ T cells (31 of IL-2 and IL-21 were more effective in controlling tumor growth as compared to CAR þ T cells grown in the presence of IL-2 (day 8, P < 0.01; day 13, P < 0.05; day 17, P < 0.05) and as compared to mice that did not receive T cells (days 8, 13, 17, P < 0.01; Fig. 5A and B) . Groups of mice receiving no T cells or CAR þ T cells grown in the presence of IL-2 showed similar rates of tumor growth (day 8, P ¼ 0.11; day 13, P ¼ 0.2; day 17, P ¼ 0.07). Tissues from mice were assessed for EGFP þ CD19 þ NALM-6 and consistent with the BLI data, we observed that the tumor burden was significantly reduced in mice receiving CAR þ T cells grown in the presence of IL-2 and IL-21, as compared to mice receiving no T cells or CAR þ T cells grown in the presence of IL-2 ( Fig. 5C and D) . The presence of NALM-6 blasts in peripheral blood was lower in the IL-2 and IL-21 (1.8 AE 0.92, mean AE SD) group as compared to mice that received CAR þ T cells cultured with IL-2 (20.4 AE 20.3, P < 0.05) or no T cells (3.8 AE 0.6, P < 0.01). There was also a significant reduction in average tumor burden in the bone marrow after administration of T cells that were cultured with IL-2 and IL-21 group (48.5 AE 4.2) as compared to IL-2 group (86.6 AE 7.8, P < 0.00001) or no T-cell group (86.6 AE 7.9, P < 0.001). The difference in average splenic tumor burden was more apparent (P < 0. Research.
on April 15, 2017. © 2011 American Association for Cancer cancerres.aacrjournals.org Downloaded from nals, we altered the aAPC to not only provide the CD19 antigen and associated costimulatory molecules, but to express a novel mutein of membrane-bound of IL-21 (Fig. 6A) . This enabled us to test the hypothesis that expressing IL-21 on the cell surface of the aAPC could replace the need for providing IL-21 as a soluble recombinant cytokine. To accomplish this, the aAPC clone no. 4 were electroporated with the SB plasmid CoOp IL-21-Fc/pT-MNDU3 and a subclone (D2) was selected based on uniform expression of mIL-21 and the other introduced cell surface markers (Fig. 6B ). PBMC electroporated with SB system to express CD19R-CD28 and propagated on g-irradiated mIL-21 þ aAPC in the absence of soluble IL-21, but in the presence of soluble IL-2 resulted in an outgrowth of CAR þ T cells (Fig. 7A) . The CAR expression (81% vs. 79%) was similar to when T cells were grown in the presence of exogenous IL-21 or with aAPC expressing mIL-21. The average fold expansion at the end of 28 days of coculture as assessed by expression of CD3 (11,700; P ¼ 0.27, not significant, NS) and CAR (14,000; P ¼ 0.17, NS) on T cells numerically expanded with mIL-21 þ aAPC was similar to the T cells propagated with soluble IL-21 (Fig. 7B) . The CAR þ T cells numerically expanded on mIL-21 þ aAPC showed specific lysis of CD19 þ target cells and a 13-fold increase in IFN-g production when cells were stimulated with CD19 þ U251T targets over control CD19 neg U251T cells (Fig. 7D) . 
Discussion
The tissue culture environment can be modified to play a critical role in the growth and function of T cells propagated in vitro. In the current study, we show that the addition of IL-21 to the culture milieu in soluble form or presented in conjunction with antigen on aAPC results in improved effector function and preservation of naïve/memory phenotype of CAR þ T cells which predicts for improved therapeutic effect in clinical trials. Initial (first generation) CARs commonly link a scFv to a single signaling moiety (e.g., CD3-z) and these typically showed a lack of sustained persistence in vivo (2) . Therefore, the CAR design was modified to add one or more costimulatory signaling domains of CD28 (4), 4-1BB (32, 33) , OX40 (34) to generate "second" or "third" generation CARs. We have previously described our second generation CAR, CD19RCD28, which provides CD19-dependent signaling through CD3z and CD28 resulting in improved persistence and antitumor effect (4) . Operating under the premise that T cells propagated in a CARdependent manner ex vivo may select for T cells with sustained proliferation in vivo, we developed a culturing system based on aAPC to selectively numerically expand CAR þ T cells. Such aAPC derived from K562 can be tailored to express cell-surface antigen (35) or intracellular antigen presented by restricting MHC (36, 37) in the context of desired and introduced T-cell costimulatory molecules (37) (38) (39) (40) . Our aAPC (clone no. 4) were also engineered to express mIL-15 and this membrane-bound cytokine is present throughout our culturing process in addition to the addition of soluble cytokines. The addition of IL-21-mediated signaling during the culturing process to selectively propagate T cells expressing a second generation CD19-specific CAR resulted in an outgrowth of T cells on aAPC with a desired phenotype and improved function when assessed in vitro and in vivo. Thus, from the perspective of manufacturing CAR þ T cells for clinical application it appears beneficial to include IL-21 in the culturing process. It has been previously shown that the tissue culture microenvironment can be altered with cytokines for improved T-cell function. For example, T cells can be primed using cytokines to augment immune responses after adoptive transfer. In some cases, this is dependent on generation of memory phenotype which requires the presence of IL-15 and IL-21 (41, 42) . This memory phenotype predicts for improved persistence as shown for T cells cultured with IL-7, IL-15, and IL-21, compared to T cells propagated with IL-2 (8, 43, 44) . Our data provide supportive evidence that not only can the CAR be manipulated, but the choice of additional cytokines influences the number and character of the propagated CAR þ T cells.
Membrane-bound cytokines (45, 46) offer an attractive approach for delivering a desired cytokine to the immediate microenvironment of the T cell-aAPC synapse along with alleviating the need to add the soluble recombinant (expensive) cytokine to the culture system and avoiding the need to procure clinical-grade cytokine for clinical applications. Membrane-bound IL-15 has been used to propagate T cells (6, 47) and NK cells (48, 49) on aAPC derived from K562 cells. Our aAPC (clone no. 4) used in this study express mIL-15 and is being used in our clinical trials infusing patient-and donor-derived CD19-specific CAR þ T cells after autologous and allogeneic hematopoietic stem-cell transplantation.
Building upon the success of aAPC expressing mIL-15, we further modified the aAPC clone no. 4 to coexpress mIL-21 and suggest that this genetic approach to aAPC design may avoid the need to add soluble recombinant IL-21 to the culture. Our data show that the SB system and aAPC platform can be manipulated to culture T cells to receive 3 coordinated signals. This was achieved by influencing intrinsic (CAR) and now extrinsic (tissue culture) factors to improve the therapeutic potential of genetically modified and propagated T cells. Activation through second generation CAR, triggered by CD3z (signal 1) and CD28 (signal 2), and common g c receptor (triggered by IL-21, signal 3) results in generation of CAR þ T cells that have an improved ability to respond to CD19 compared to T cells cultured without IL-21. The ability to augment signal 3 leads to an outgrowth of CAR þ T cells on aAPC that have desired properties for use in clinical trials.
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